Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03076554 trial: what clinicians have said so far
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
- NCT03076554 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT03076554 (avelumab in thymoma and thymic carcinoma after platinum-based chemotherapy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03076554 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Thymoma; Thymic Carcinoma
- Interventions
- Avelumab
- Arms
- Arm 1 Avelumab · Experimental
- Enrollment
- 56
- Primary outcomes
- Safety and tolerability of Avelumab based on NCI-CTCAE v4.0
- Objective Response Rate (ORR) based on RECIST 1.1 criteria
- Sponsor
- National Cancer Institute (NCI)
- Start
- Apr 19, 2017
- Primary completion
- Mar 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03076554 · updated Oct 29, 2026
Publications
linked from the registry- Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015 May;88(2):154-9. doi: 10.1016/j.lungcan.2015.03.003. Epub 2015 Mar 10. PubMed 25799277
- Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015 Mar;10(3):500-8. doi: 10.1097/JTO.0000000000000429. PubMed 25402569
- Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. PubMed 34393061